Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP2CA | P67775 | 7/20 | 0.62 |
| ▸ | PTPA | Q15257 | 5/20 | 0.62 |
| ▸ | PPP5C | P53041 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | PPP1CC | P36873 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21298445 | 0.97 | PTPA (0.66) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL22965087 | 0.77 | PTPA (1.00) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL21298444 | 0.77 | PTPA (1.00) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL23008659 | 0.77 | PTPA (1.00) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| Tautomycin SCHEMBL23008660 | 0.77 | PTPA (1.00) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| SCHEMBL15381937 | 0.56 | PPP2CA (0.57) | PPP2CAPTPAPPP5CPTPN1PPP1CC | |
| SCHEMBL12631267 | 0.47 | MAPT (0.49) | HPGD | |
| SCHEMBL12153331 | 0.46 | CA1 (0.48) | ALDH1A1 | |
| SCHEMBL10844122 | 0.45 | — | — | |
| SCHEMBL12153332 | 0.45 | CA1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571475-B1 | Anti-CD70 and BCR-ABL inhibitor combination therapy | UNIVERSITY OF BERN (CH) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571475-B1 | Anti-CD70 and BCR-ABL inhibitor combination therapy | ABL1, BCR, ZAP70 | PPP2CA 1024/4885PTPA 288/4885PPP5C 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.